[276 Pages Report] The global swine respiratory diseases treatment market size is expected to reach a valuation of US$ 2.0 Billion by the end of 2022, and further expand at a CAGR of 6.3% from 2022 to 2032. The market is likely to reach a valuation of US$ 3.6 Billion by the end of 2032. Mycoplasma under the causative agent segment is leading the swine respiratory diseases treatment market and it held a share of about 35.2% in 2021.
Based on the severity and duration of the observable condition, swine respiratory disorders can be grouped into two main categories: those that affect a significant number of pigs and may be hazardous but only last a short while, and those that affect a large number of pigs for an extended period of time. Costs of diseases in the first category are limited rather than continuing.
Swine influenza, classical swine fever, pneumonic pseudorabies, porcine circovirus-associated illness, and pig reproductive and respiratory syndrome (PRRS) are categorized among them. Although pathogenic viruses may survive in a herd, outbreaks of overt sickness are usually self-limiting. Mycoplasma pneumonia and pleuropneumonia are the most common syndromes in the second category like rhinitis atrophic.
| Attributes | Key Statistics |
|---|---|
| Global Swine Respiratory Diseases Treatment Market Estimated Size (2022E) | US$ 1,978.1 Million |
| Projected Market Valuation (2032F) | US$ 3,649.5 Million |
| Value-based CAGR (2022 to 2032) | 6.3% |
| Collective Value Share: Top 5 Countries | 61.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global swine respiratory diseases treatment market held approximately 1.9% of the overall veterinary services market, which was worth ~US$ 99.5 Billion in 2021. Sales of swine respiratory disease treatment services expanded at a CAGR of 6.1% from 2012 to 2021.
Demand for swine respiratory disease treatment options is on the rise due to the increasing number of foodborne and zoonotic diseases. According to the most recent annual report on food diseases issued by the European Food Safety Authority (EFSA) and the European Center for Disease Prevention and Control (ECDC) in February 2021, foodborne infections are on the rise compared to the previous year, with pathogenic bacteria such as campylobacter spp. being the most common cause.
Around 5175 food outbreaks were documented, accounting for 49463 clinical cases, 3859 hospital admissions, and 60 deaths (+50% compared to the previous year). Salmonella, norovirus, escherichia coli, yersinia enterocolitica, cryptosporidium parvum, and campylobacter jejuni were the most common etiological agents found, while the most common causes of infection were eggs & egg products, bakery items, hog meat, processed foods, water, crustaceans, and vegetables.
Additionally, the market for swine respiratory diseases treatment is anticipated to grow in terms of research & development (R&D) spending and revenue owing to external partnerships and strategic alliances between industries and academia. For instance, in September 2022, Zoetis acquired NewMetrica, which had developed cutting-edge digital instruments in the form of standardized questionnaires that were intended to evaluate health-related quality of life (HRQL) in nonverbal species, as a strategic addition to their companion animal portfolio. Thus, owing to the aforementioned factors, the global swine respiratory diseases treatment market is expected to grow at a CAGR of 6.3% during the forecast period from 2022 to 2032.
The market is likely to provide an opportunistic perspective owing to various initiatives by governments in emerging countries. Government bodies are investing significantly in healthcare infrastructure modernization, which is expected to bolster access to advanced healthcare services. This factor is set to fuel demand for upgraded technologies, thereby creating an appealing opportunity in the global swine respiratory diseases treatment market.
In high-income economies like the UK and the USA, there will likely be a greater emphasis on innovation to prevent zoonotic diseases combined with biotechnology breakthroughs, which will create a favorable environment for the development of veterinary therapeutics. These methods include systems biology, synthetic biology, and next-generation sequencing among others. Additionally, maintaining investments in multidisciplinary research may accelerate the time to market for new products and enhance the efficiency of therapy development.
The large market potential for veterinary therapeutics is expected to emerge throughout the forecast period as a result of growing economies in emerging markets like Latin America and Asia Pacific. The potential that these markets present are due to a large number of factors, including the increasing cost of living for the urban middle-class population in these regions, which further surges per-capita meat consumption and fuels the need for more effective livestock farming.
Principal Consultant
Stringent regulations put forward by the USA Food & Drug Administration (FDA) to limit the use of antibiotics for farm animals and the rising cost of innovation-dampening Research and Development investments can hamper the market in the forecast period. If antibiotics are administered to livestock that is raised for food such as swine and other animals, they may lose their efficacy in humans. Antibiotic-resistant bacteria known as superbugs are on the rise as a result of the widespread use of antibiotics in both humans and animals.
The cost of drug innovation has been increasing, as compared to earlier years. The trend is similar for animal healthcare. This is primarily attributed to a limited scope of research for newer diseases in livestock animals. Due to this, drug makers are investing more in the development of innovative drugs for diseases, which are already highly mature. This further raises Research and Development spending and dampens return on investment (ROI). These factors cumulatively propose a negative effect on developmental growth in the swine respiratory diseases treatment market.
Rising Prevalence of Zoonotic Diseases in the USA to Push Growth by 2032
The USA dominates the North American swine respiratory diseases treatment market and held a total share of about 52.9% in 2021. It is expected to continue to experience the same growth rate throughout the forecast period.
Owing to the increased swine respiratory diseases related deaths, high consumption of animal meats, and growing prevalence of zoonotic diseases, producers or manufacturers operating in the market are presented with new growth opportunities to develop unique preventive measures, which would further boost the market in the USA
Surging Need for H1N1 Influenza Treatment in Canada to Drive the Industry Forward
Canada held approximately 47.1% of the share in the North American swine respiratory diseases treatment market in 2021 and it is expected to showcase growth at a lucrative CAGR of 6.7% during the forecast period.
Influenza viruses are frequently found in pigs, who can be infected by humans, birds, or other pigs. Predominant influenza subtypes prevalent in pigs in Canada are H1N1, H1N2, and H3N2. Swine influenza viruses do not generally infect humans; however, these viruses have occasionally infected humans.
Cases mainly emerge because of direct or indirect contact with pigs in numerous settings such as farms or agricultural fairs. The Canadian Food Inspection Agency (CFIA) advises veterinarians and producers to maintain strict biosecurity measures to reduce any hazards to human or animal health.
Rising Cases of Swine Fever in Pigs to Propel Growth in Germany by 2032
Germany is set to exhibit a CAGR of nearly 5.8% in the Europe swine respiratory diseases treatment market during the forecast period. Germany is becoming increasingly popular when it comes to health and innovation. With the surging prevalence of influenza A (H1), as well as increasing surveillance and management measures of the disease implemented by the World Health Organization (WHO), the demand for swine respiratory disease treatment options will grow at a rapid pace.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Mycoplasma-based Swine Diseases to Exhibit High Growth in the Upcoming Decade
Mycoplasma-based causative agents are expected to witness high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 35.2% in 2021. The major pathogen of enzootic pneumonia, a chronic respiratory disease in pigs, is mycoplasma hyopneumoniae. Infections caused by mycoplasma hyopneumoniae are common in practically all swine production locations, which leads to huge economic losses due to increased medicine consumption and lower pig performance.
Common Swine Diseases Are Expected to Be Treated with Antibiotics
The drugs segment is expected to create high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 63.8% in 2021. Antibiotic use during all stages of growth enhances the efficiency and efficacy of body weight gain, lowers death rates & comorbidities, reduces subclinical disease, and improves pig health.
Veterans Prefer Oral Route of Administration to Treat Swine Fever Disease
The oral route of administration is expected to exhibit high growth at a CAGR of 6.3% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 86.3% in 2021. The oral route of administration is the most common form of medication administration in farm animals. Medications are mixed with animal feed for ease of ingestion, which would push the segment.
Veterinary Hospitals to Offer Advanced Treatment Options for Swine Bacterial Diseases
Veterinary hospitals held the highest swine respiratory diseases treatment market share of 37.0% in 2021. Pigs are considered to be better medical research subjects than mice as their size, physiology, and genetic makeup are more similar to humans.
With several competitors in the swine respiratory diseases treatment market, the overall industry is highly fragmented. To meet rising consumer demand and expand their customer base, these companies are implementing various methods such as mergers & acquisitions, partnerships & collaborations, and new product launches.
Some of the recent developments in the swine respiratory diseases treatment market are given below:
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | US$ 1,978.1 Million |
| Projected Market Valuation (2032) | US$ 3,649.5 Million |
| Value-based CAGR (2022 to 2032) | 6.3% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | Value (US$ Million) |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, North Africa, and South Africa |
| Key Market Segments Covered | Causative Agent, Treatment, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Zoetis; Bayer AG; Boehringer Ingelheim GmbH; Elanco Animal Health (Sub. Eli Lilly); Virbac; Norbrook; Ceva Santé Animale; Intervet Inc., (Sub. Merck & Co. Inc.); Vetoquinol SA; Bimeda Inc.; Kyoritsu Seiyaku Corporation; HIPRA; Agrilabs, Inc.; Ashish LifeSciences Ltd.; Cipla Pharmaceuticals.; Thermo Fisher Scientific Inc.; Huvepharma |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The global swine respiratory diseases treatment market was worth US$ 1,852.0 Million in 2021 and is set to expand 1.8x over the next ten years.
The swine respiratory diseases treatment market is expected to reach US$ 3,649.5 Million by the end of 2032, with sales revenue set to register a 6.3% CAGR.
Emergence of biologics & specialty care, growing awareness & affordability of therapeutics for livestock, and shifting distribution of drugs from traditional channels are some of the key trends in the swine respiratory diseases treatment market.
The USA, Canada, China, the Philippines, and South Korea are expected to drive demand in the swine respiratory diseases treatment market.
North America is one of the key regions, with the USA accounting for about 52.9% of the region’s swine respiratory diseases treatment market in the year 2021.
The swine respiratory disease treatment market in Japan is expected to register growth at a CAGR of 5.2% over the next ten years.
The swine respiratory disease treatment market in Germany is expected to register growth at a CAGR of 5.8% over the next ten years.
China, the USA, and the Philippines are the key producers of swine respiratory diseases treatment
Zoetis, Bayer AG, Boehringer Ingelheim GmbH, Elanco Animal Health (Sub. Eli Lilly), Virbac, Norbrook, Ceva Santé Animale, Intervet Inc. (Sub. Merck & Co. Inc.), Vetoquinol SA, Bimeda, Inc., Kyoritsu Seiyaku Corporation, HIPRA, Agrilabs, Inc., Ashish LifeSciences Ltd., Cipla Pharmaceuticals., Thermo Fisher Scientific Inc., and Huvepharma, are some of the key players in the swine respiratory diseases treatment market.
The global swine respiratory disease treatment market in South Korea is expected to register growth at a CAGR of 6.1% over the next ten years.
1. Executive Summary | Swine Respiratory Diseases Treatment Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Disease Epidemiology 4.2. Key Promotional Strategies - by Manufacturers 4.3. Regulatory Scenario 4.4. Reimbursement Scenario 4.5. Porter’s Analysis 4.6. PESTLE Analysis 4.7. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Veterinary Services Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. New Product Launches 5.2.2. Rise in Consumption of Pork 5.2.3. Increasing Requirement of Quality of Life in Animal Healthcare 5.2.4. Increasing Research and Development Activities 5.2.5. Adoption of Veterinary Vaccination 5.2.6. Introduction of Novel and Advanced Technologies 5.2.7. Government Investments in Veterinary Diseases 5.2.8. Increasing Prevalence of Porcine Reproductive and Respiratory Syndrome 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Causative Agent 6.1.2. By Treatment 6.1.3. By Route of Administration 6.1.4. By Distribution Channel 6.1.5. By Country 6.2. 2021 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Causative Agent 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis and Forecast By Causative Agent, 2012 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Causative Agent, 2022 to 2032 8.3.1. Virus 8.3.2. Mycoplasma 8.3.3. Bacteria 8.3.4. Others 8.4. Market Attractiveness Analysis By Causative Agent 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Treatment 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Treatment, 2012 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Treatment, 2022 to 2032 9.3.1. Drugs 9.3.1.1. Antibiotics 9.3.1.2. Others 9.3.2. Vaccines 9.4. Market Attractiveness Analysis By Treatment 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Route of Administration 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis, By Route of Administration, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032 10.3.1. Oral 10.3.2. Parenteral 10.4. Market Attractiveness Analysis By Route of Administration 11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2012 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis Forecast By Distribution Channel, 2022 to 2032 11.3.1. Veterinary Hospitals 11.3.2. Veterinary Clinics 11.3.3. Pharmacies 11.3.4. Others 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021 12.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 13.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 13.4.1. By Country 13.4.1.1. United States of America 13.4.1.2. Canada 13.4.2. By Causative Agent 13.4.3. By Treatment 13.4.4. By Route of Administration 13.4.5. By Distribution Channel 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Causative Agent 13.5.3. By Treatment 13.5.4. By Route of Administration 13.5.5. By Distribution Channel 13.6. Market Trends 13.7. Key Market Participants - Intensity Mapping 13.8. Drivers and Restraints - Impact Analysis 13.9. Country-Level Analysis & Forecast 13.9.1. USA Market Analysis 13.9.1.1. .Introduction 13.9.1.2. Market Analysis and Forecast by Market Taxonomy 13.9.1.2.1. By Causative Agent 13.9.1.2.2. By Treatment 13.9.1.2.3. By Route of Administration 13.9.1.2.4. By Distribution Channel 13.9.2. Canada Market Analysis 13.9.2.1. Introduction 13.9.2.2. Market Analysis and Forecast by Market Taxonomy 13.9.2.2.1. By Causative Agent 13.9.2.2.2. By Treatment 13.9.2.2.3. By Route of Administration 13.9.2.2.4. By Distribution Channel 14. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2012 to 2021 14.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 14.4.1. By Country 14.4.1.1. Mexico 14.4.1.2. Brazil 14.4.1.3. Argentina 14.4.1.4. Rest of Latin America 14.4.2. By Causative Agent 14.4.3. By Treatment 14.4.4. By Route of Administration 14.4.5. By Distribution Channel 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Causative Agent 14.5.3. By Treatment 14.5.4. By Route of Administration 14.5.5. By Distribution Channel 14.6. Market Trends 14.7. Key Market Participants - Intensity Mapping 14.8. Drivers and Restraints - Impact Analysis 14.9. Country-Level Analysis & Forecast 14.9.1. Mexico Market Analysis 14.9.1.1. Introduction 14.9.1.2. Market Analysis and Forecast by Market Taxonomy 14.9.1.2.1. By Causative Agent 14.9.1.2.2. By Treatment 14.9.1.2.3. By Route of Administration 14.9.1.2.4. By Distribution Channel 14.9.2. Brazil Market Analysis 14.9.2.1. Introduction 14.9.2.2. Market Analysis and Forecast by Market Taxonomy 14.9.2.2.1. By Causative Agent 14.9.2.2.2. By Treatment 14.9.2.2.3. By Route of Administration 14.9.2.2.4. By Distribution Channel 14.9.3. Argentina Market Analysis 14.9.3.1. Introduction 14.9.3.2. Market Analysis and Forecast by Market Taxonomy 14.9.3.2.1. By Causative Agent 14.9.3.2.2. By Treatment 14.9.3.2.3. By Route of Administration 14.9.3.2.4. By Distribution Channel 15. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2012 to 2021 15.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 15.4.1. By Country 15.4.1.1. Germany 15.4.1.2. Italy 15.4.1.3. France 15.4.1.4. United Kingdom 15.4.1.5. Spain 15.4.1.6. BENELUX 15.4.1.7. Russia 15.4.1.8. Nordic Countries 15.4.1.9. Rest of Europe 15.4.2. By Causative Agent 15.4.3. By Treatment 15.4.4. By Route of Administration 15.4.5. By Distribution Channel 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Causative Agent 15.5.3. By Treatment 15.5.4. By Route of Administration 15.5.5. By Distribution Channel 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 15.9. Country-Level Analysis & Forecast 15.9.1. Germany Market Analysis 15.9.1.1. Introduction 15.9.1.2. Market Analysis and Forecast by Market Taxonomy 15.9.1.2.1. By Causative Agent 15.9.1.2.2. By Treatment 15.9.1.2.3. By Route of Administration 15.9.1.2.4. By Distribution Channel 15.9.2. Italy Market Analysis 15.9.2.1. Introduction 15.9.2.2. Market Analysis and Forecast by Market Taxonomy 15.9.2.2.1. By Causative Agent 15.9.2.2.2. By Treatment 15.9.2.2.3. By Route of Administration 15.9.2.2.4. By Distribution Channel 15.9.3. France Market Analysis 15.9.3.1. Introduction 15.9.3.2. Market Analysis and Forecast by Market Taxonomy 15.9.3.2.1. By Causative Agent 15.9.3.2.2. By Treatment 15.9.3.2.3. By Route of Administration 15.9.3.2.4. By Distribution Channel 15.9.4. UK Market Analysis 15.9.4.1. Introduction 15.9.4.2. Market Analysis and Forecast by Market Taxonomy 15.9.4.2.1. By Causative Agent 15.9.4.2.2. By Treatment 15.9.4.2.3. By Route of Administration 15.9.4.2.4. By Distribution Channel 15.9.5. Spain Market Analysis 15.9.5.1. Introduction 15.9.5.2. Market Analysis and Forecast by Market Taxonomy 15.9.5.2.1. By Causative Agent 15.9.5.2.2. By Treatment 15.9.5.2.3. By Route of Administration 15.9.5.2.4. By Distribution Channel 15.9.6. BENELUX Market Analysis 15.9.6.1. Introduction 15.9.6.2. Market Analysis and Forecast by Market Taxonomy 15.9.6.2.1. By Causative Agent 15.9.6.2.2. By Treatment 15.9.6.2.3. By Route of Administration 15.9.6.2.4. By Distribution Channel 15.9.7. Russia Market Analysis 15.9.7.1. Introduction 15.9.7.2. Market Analysis and Forecast by Market Taxonomy 15.9.7.2.1. By Causative Agent 15.9.7.2.2. By Treatment 15.9.7.2.3. By Route of Administration 15.9.7.2.4. By Distribution Channel 15.9.8. Nordic Countries Market Analysis 15.9.8.1. Introduction 15.9.8.2. Market Analysis and Forecast by Market Taxonomy 15.9.8.2.1. By Causative Agent 15.9.8.2.2. By Treatment 15.9.8.2.3. By Route of Administration 15.9.8.2.4. By Distribution Channel 16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 16.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 16.4.1. By Country 16.4.1.1. China 16.4.1.2. Japan 16.4.1.3. South Korea 16.4.2. By Causative Agent 16.4.3. By Treatment 16.4.4. By Route of Administration 16.4.5. By Distribution Channel 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Causative Agent 16.5.3. By Treatment 16.5.4. By Route of Administration 16.5.5. By Distribution Channel 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 16.9. Country-Level Analysis & Forecast 16.9.1. China Market Analysis 16.9.1.1. Introduction 16.9.1.2. Market Analysis and Forecast by Market Taxonomy 16.9.1.2.1. By Causative Agent 16.9.1.2.2. By Treatment 16.9.1.2.3. By Route of Administration 16.9.1.2.4. By Distribution Channel 16.9.2. Japan Market Analysis 16.9.2.1. Introduction 16.9.2.2. Market Analysis and Forecast by Market Taxonomy 16.9.2.2.1. By Causative Agent 16.9.2.2.2. By Treatment 16.9.2.2.3. By Route of Administration 16.9.2.2.4. By Distribution Channel 16.9.3. South Korea Market Analysis 16.9.3.1. Introduction 16.9.3.2. Market Analysis and Forecast by Market Taxonomy 16.9.3.2.1. By Causative Agent 16.9.3.2.2. By Treatment 16.9.3.2.3. By Route of Administration 16.9.3.2.4. By Distribution Channel 17. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 17.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 17.4.1. By Country 17.4.1.1. India 17.4.1.2. Indonesia 17.4.1.3. Malaysia 17.4.1.4. Thailand 17.4.1.5. Rest of South Asia 17.4.2. By Causative Agent 17.4.3. By Treatment 17.4.4. By Route of Administration 17.4.5. By Distribution Channel 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Causative Agent 17.5.3. By Treatment 17.5.4. By Route of Administration 17.5.5. By Distribution Channel 17.6. Market Trends 17.7. Key Market Participants - Intensity Mapping 17.8. Drivers and Restraints - Impact Analysis 17.9. Country-Level Analysis & Forecast 17.9.1. India Market Analysis 17.9.1.1. Introduction 17.9.1.2. Market Analysis and Forecast by Market Taxonomy 17.9.1.2.1. By Causative Agent 17.9.1.2.2. By Treatment 17.9.1.2.3. By Route of Administration 17.9.1.2.4. By Distribution Channel 17.9.2. Indonesia Market Analysis 17.9.2.1. Introduction 17.9.2.2. Market Analysis and Forecast by Market Taxonomy 17.9.2.2.1. By Causative Agent 17.9.2.2.2. By Treatment 17.9.2.2.3. By Route of Administration 17.9.2.2.4. By Distribution Channel 17.9.3. Malaysia Market Analysis 17.9.3.1. Introduction 17.9.3.2. Market Analysis and Forecast by Market Taxonomy 17.9.3.2.1. By Causative Agent 17.9.3.2.2. By Treatment 17.9.3.2.3. By Route of Administration 17.9.3.2.4. By Distribution Channel 17.9.4. Thailand Market Analysis 17.9.4.1. Introduction 17.9.4.2. Market Analysis and Forecast by Market Taxonomy 17.9.4.2.1. By Causative Agent 17.9.4.2.2. By Treatment 17.9.4.2.3. By Route of Administration 17.9.4.2.4. By Distribution Channel 17.9.5. Rest of South Asia Market Analysis 17.9.5.1. Introduction 17.9.5.2. Market Analysis and Forecast by Market Taxonomy 17.9.5.2.1. By Causative Agent 17.9.5.2.2. By Treatment 17.9.5.2.3. By Route of Administration 17.9.5.2.4. By Distribution Channel 18. Oceania Market 2012 to 2021 and Forecast 2022 to 2032 18.1. Introduction 18.2. Pricing Analysis 18.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 18.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 18.4.1. By Country 18.4.1.1. Australia 18.4.1.2. New Zealand 18.4.2. By Causative Agent 18.4.3. By Treatment 18.4.4. By Route of Administration 18.4.5. By Distribution Channel 18.5. Market Attractiveness Analysis 18.5.1. By Country 18.5.2. By Causative Agent 18.5.3. By Treatment 18.5.4. By Route of Administration 18.5.5. By Distribution Channel 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country-Level Analysis & Forecast 18.8.1. Australia Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Causative Agent 18.8.1.2.2. By Treatment 18.8.1.2.3. By Route of Administration 18.8.1.2.4. By Distribution Channel 18.8.2. New Zealand Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Causative Agent 18.8.2.2.2. By Treatment 18.8.2.2.3. By Route of Administration 18.8.2.2.4. By Distribution Channel 19. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032 19.1. Introduction 19.2. Pricing Analysis 19.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 19.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 19.4.1. By Country 19.4.1.1. GCC Countries 19.4.1.2. Turkey 19.4.1.3. South Africa 19.4.1.4. North Africa 19.4.1.5. Rest of Middle East and Africa 19.4.2. By Causative Agent 19.4.3. By Treatment 19.4.4. By Route of Administration 19.4.5. By Distribution Channel 19.5. Market Attractiveness Analysis 19.5.1. By Country 19.5.2. By Causative Agent 19.5.3. By Treatment 19.5.4. By Route of Administration 19.5.5. By Distribution Channel 19.6. Market Trends 19.7. Key Market Participants - Intensity Mapping 19.8. Drivers and Restraints - Impact Analysis 19.9. Country-Level Analysis & Forecast 19.9.1. GCC Countries Market Analysis 19.9.1.1. Introduction 19.9.1.2. Market Analysis and Forecast by Market Taxonomy 19.9.1.2.1. By Causative Agent 19.9.1.2.2. By Treatment 19.9.1.2.3. By Route of Administration 19.9.1.2.4. By Distribution Channel 19.9.2. Turkey Market Analysis 19.9.2.1. Introduction 19.9.2.2. Market Analysis and Forecast by Market Taxonomy 19.9.2.2.1. By Causative Agent 19.9.2.2.2. By Treatment 19.9.2.2.3. By Route of Administration 19.9.2.2.4. By Distribution Channel 19.9.3. South Africa Market Analysis 19.9.3.1. Introduction 19.9.3.2. Market Analysis and Forecast by Market Taxonomy 19.9.3.2.1. By Causative Agent 19.9.3.2.2. By Treatment 19.9.3.2.3. By Route of Administration 19.9.3.2.4. By Distribution Channel 19.9.4. North Africa Market Analysis 19.9.4.1. Introduction 19.9.4.2. Market Analysis and Forecast by Market Taxonomy 19.9.4.2.1. By Causative Agent 19.9.4.2.2. By Treatment 19.9.4.2.3. By Route of Administration 19.9.4.2.4. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Concentration 20.3. Market Share Analysis of Top Players 20.4. Market Presence Analysis 20.4.1. By Regional footprint of Players 20.4.2. Product foot print by Players 20.4.3. Channel Foot Print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Zoetis 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Profitability by Market Segments (Product/Channel/Region) 21.3.1.4. Sales Footprint 21.3.1.5. Key Financials 21.3.1.6. SWOT Analysis 21.3.1.7. Strategy Overview 21.3.2. Bayer AG 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Profitability by Market Segments (Product/Channel/Region) 21.3.2.4. Sales Footprint 21.3.2.5. Key Financials 21.3.2.6. SWOT Analysis 21.3.2.7. Strategy Overview 21.3.3. Boehringer Ingelheim GmbH 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Profitability by Market Segments (Product/Channel/Region) 21.3.3.4. Sales Footprint 21.3.3.5. Key Financials 21.3.3.6. SWOT Analysis 21.3.3.7. Strategy Overview 21.3.4. Elanco Animal Health (Sub. Eli Lilly) 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Profitability by Market Segments (Product/Channel/Region) 21.3.4.4. Sales Footprint 21.3.4.5. Key Financials 21.3.4.6. SWOT Analysis 21.3.4.7. Strategy Overview 21.3.5. Virbac 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Profitability by Market Segments (Product/Channel/Region) 21.3.5.4. Sales Footprint 21.3.5.5. Key Financials 21.3.5.6. SWOT Analysis 21.3.5.7. Strategy Overview 21.3.6. Norbrook 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Profitability by Market Segments (Product/Channel/Region) 21.3.6.4. Sales Footprint 21.3.6.5. Key Financials 21.3.6.6. SWOT Analysis 21.3.6.7. Strategy Overview 21.3.7. Ceva Santé Animale 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Profitability by Market Segments (Product/Channel/Region) 21.3.7.4. Sales Footprint 21.3.7.5. Key Financials 21.3.7.6. SWOT Analysis 21.3.7.7. Strategy Overview 21.3.8. Intervet Inc., (Sub. Merck & Co. Inc.) 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Profitability by Market Segments (Product/Channel/Region) 21.3.8.4. Sales Footprint 21.3.8.5. Key Financials 21.3.8.6. SWOT Analysis 21.3.8.7. Strategy Overview 21.3.9. Vetoquinol SA 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Profitability by Market Segments (Product/Channel/Region) 21.3.9.4. Sales Footprint 21.3.9.5. Key Financials 21.3.9.6. SWOT Analysis 21.3.9.7. Strategy Overview 21.3.10. Bimeda Inc., 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Profitability by Market Segments (Product/Channel/Region) 21.3.10.4. Sales Footprint 21.3.10.5. Key Financials 21.3.10.6. SWOT Analysis 21.3.10.7. Strategy Overview 21.3.11. Kyoritsu Seiyaku Corporation 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Profitability by Market Segments (Product/Channel/Region) 21.3.11.4. Sales Footprint 21.3.11.5. Key Financials 21.3.11.6. SWOT Analysis 21.3.11.7. Strategy Overview 21.3.12. HIPRA 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Profitability by Market Segments (Product/Channel/Region) 21.3.12.4. Sales Footprint 21.3.12.5. Key Financials 21.3.12.6. SWOT Analysis 21.3.12.7. Strategy Overview 21.3.13. Agrilabs, Inc., 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Profitability by Market Segments (Product/Channel/Region) 21.3.13.4. Sales Footprint 21.3.13.5. Key Financials 21.3.13.6. SWOT Analysis 21.3.13.7. Strategy Overview 21.3.14. Ashish Lifesciences Ltd., 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Profitability by Market Segments (Product/Channel/Region) 21.3.14.4. Sales Footprint 21.3.14.5. Key Financials 21.3.14.6. SWOT Analysis 21.3.14.7. Strategy Overview 21.3.15. Cipla Pharmaceuticals. 21.3.15.1. Overview 21.3.15.2. Product Portfolio 21.3.15.3. Profitability by Market Segments (Product/Channel/Region) 21.3.15.4. Sales Footprint 21.3.15.5. Key Financials 21.3.15.6. SWOT Analysis 21.3.15.7. Strategy Overview 21.3.16. Thermo Fisher Scientific Inc., 21.3.16.1. Overview 21.3.16.2. Product Portfolio 21.3.16.3. Profitability by Market Segments (Product/Channel/Region) 21.3.16.4. Sales Footprint 21.3.16.5. Key Financials 21.3.16.6. SWOT Analysis 21.3.16.7. Strategy Overview 21.3.17. Huvepharma. 21.3.17.1. Overview 21.3.17.2. Product Portfolio 21.3.17.3. Profitability by Market Segments (Product/Channel/Region) 21.3.17.4. Sales Footprint 21.3.17.5. Key Financials 21.3.17.6. SWOT Analysis 21.3.17.7. Strategy Overview 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Swine Respiratory Diseases Treatment Market
